Hospital Ramón y Cajal -ko ikertzaileekin lankidetzan egindako argitalpenak (18)

2024

  1. Long-term outcome and risk stratification in compensated advanced chronic liver disease after HCV-cure

    Hepatology

  2. Post-treatment LSM rather than change during treatment predicts decompensation in patients with cACLD after HCV cure

    Journal of Hepatology, Vol. 81, Núm. 1, pp. 76-83

  3. Stroke in critically ill patients with respiratory failure due to COVID-19: Disparities between low-middle and high-income countries

    Heart and Lung, Vol. 68, pp. 131-144

  4. Total Neoadjuvant Therapy Approach for the Treatment of Locally Advanced Rectal Cancer: Where Do We Stand?

    Oncology (Switzerland), Vol. 102, Núm. 7, pp. 646-657

2023

  1. CT-derived liver and spleen volume accurately diagnose clinically significant portal hypertension in patients with hepatocellular carcinoma

    JHEP Reports, Vol. 5, Núm. 3

2020

  1. A Model Based on Noninvasive Markers Predicts Very Low Hepatocellular Carcinoma Risk After Viral Response in Hepatitis C Virus–Advanced Fibrosis

    Hepatology, Vol. 72, Núm. 6, pp. 1924-1934

  2. Plasma metabolomic fingerprint of advanced cirrhosis stages among HIV/HCV-coinfected and HCV-monoinfected patients

    Liver International, Vol. 40, Núm. 9, pp. 2215-2227

  3. Prevalence, features and predictive factors of liver nodules in Fontan surgery patients: The VALDIG Fonliver prospective cohort

    Journal of Hepatology, Vol. 72, Núm. 4, pp. 702-710

2019

  1. Real-world evidence of the effectiveness of ombitasvir-paritaprevir/r ± dasabuvir ± ribavirin in patients monoinfected with chronic hepatitis C or coinfected with human immunodeficiency virus-1 in Spain

    PLoS ONE, Vol. 14, Núm. 11

2017

  1. Effectiveness and safety of sofosbuvir-based regimens plus an NS5A inhibitor for patients with HCV genotype 3 infection and cirrhosis. Results of a multicenter real-life cohort

    Journal of Viral Hepatitis, Vol. 24, Núm. 4, pp. 304-311

  2. Effectiveness, safety and clinical outcomes of direct-acting antiviral therapy in HCV genotype 1 infection: Results from a Spanish real-world cohort

    Journal of Hepatology, Vol. 66, Núm. 6, pp. 1138-1148

  3. Real-World Effectiveness and Safety of Oral Combination Antiviral Therapy for Hepatitis C Virus Genotype 4 Infection

    Clinical Gastroenterology and Hepatology, Vol. 15, Núm. 6, pp. 945-949.e1

2016

  1. Human immunodeficiency virus infection does not worsen prognosis of liver transplantation for hepatocellular carcinoma

    Hepatology, Vol. 63, Núm. 2, pp. 488-498

2015

  1. Association Between Severe Portal Hypertension and Risk of Liver Decompensation in Patients With Hepatitis C, Regardless of Response to Antiviral Therapy

    Clinical Gastroenterology and Hepatology, Vol. 13, Núm. 10, pp. 1846-1853.e1

  2. Influenza vaccination during the first 6 months after solid organ transplantation is efficacious and safe

    Clinical Microbiology and Infection, Vol. 21, Núm. 11, pp. 1040.e11-1040.e18

2013

  1. Prognostic value of hepatic venous pressure gradient in patients with compensated chronic hepatitis C-related cirrhosis

    Scandinavian Journal of Gastroenterology, Vol. 48, Núm. 4, pp. 487-495

2010

  1. Peginterferon plus ribavirin and sustained virological response in HCV-related cirrhosis: Outcomes and factors predicting response

    American Journal of Gastroenterology, Vol. 105, Núm. 10, pp. 2164-2172

2008

  1. Impact of immunosuppression without steroids on rejection and hepatitis C virus evolution after liver transplantation: Results of a prospective randomized study

    Liver Transplantation, Vol. 14, Núm. 12, pp. 1752-1760